Neurologic Stem Cell Treatment Study
MD Stem Cells · NCT02795052
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 500
- US sites recruiting
- 2
- Study start
- June 2016
- Record last updated
- June 26, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Being studied: Intravenous and Intranasal BMSC
Conditions: Neurologic Disorders; Nervous System Diseases; Neurodegenerative Diseases; Neurological Disorders; Stroke; Traumatic Brain Injury; Cadasil; Chronic Traumatic Encephalopathy; Cerebral Infarction; Cerebral Ischemia; Cerebral Stroke; Cerebral Hemorrhage; Parkinson; Multi-System Degeneration; MSA - Multiple System Atrophy; Progressive Supranuclear Palsy; ALS; Amyotrophic Lateral Sclerosis; Neuropathy; Diabetic Neuropathies; Alzheimer Disease; Dementia; Frontotemporal Dementia; Lewy Body Disease; Cognitive Impairment; Lewy Body Variant of Alzheimer Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.
- Be at least 6 months post-onset of the disease.
- If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.
- In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
- Be over the age of 18 and capable of providing informed consent.
- Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.
Exclusion Criteria
- All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
- Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.
- Patients must be capable of providing informed consent.
- In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
- Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
- Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.
Recruiting US locations
MD Stem Cells
Westport, CT 06880
Site contact: Steven Levy, MD, Study Director · 203-423-9494 · stevenlevy@mdstemcells.com
MD Stem Cells
Coral Springs, FL 33065
Site contact: Steven Levy, MD, Study Director · 203-423-9494 · stevenlevy@mdstemcells.com
Study contacts (from the official record)
- Steven Levy, MD · 203-423-9494 · stevenlevy@mdstemcells.com
Similar studies in Connecticut
All diabetes studies in Connecticut →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Waterbury, CT + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Manchester, CT + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Waterford, CT + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Stamford, CT + 11 other US sites
- Eligibility basics
- Ages 10–17